Impact of Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers and Thiazide Diuretics on Survival of Ovarian Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose We investigated the impact of four types of antihypertensive medications, angiotensin receptor blockers (ARBs), beta blockers (BBs; both selective and non-selective), calcium channel blockers (CCBs), and thiazide diuretics (TDs) on survival outcomes in epithelial ovarian cancer (EOC). Materials and Methods A single-institutional retrospective chart review of 878 patients with EOC was performed. Survival was compared according to use of the four antihypertensive medications during primary treatment. Propensity score matching (ratio 1:3) was performed to control possible associated covariates, such as age, International Federation of Gynecology and Obstetrics stage, residual status after primary debulking surgery, and co-morbidity. Results Among 878 patients, 56 patients (6.4%) were ARB users, 62 (7.1%) were BB users, 107 (12.2%) were CCBs users and 32 (3.6%) used TDs. Median progression-free survival (PFS) for ARB, BB, and CCB users was 37.8, 27.2, and 23.6 months compared with 33.6 months for non-users. ARB was associated with 35% decreased risk of disease progression (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.42 to 0.99; p=0.046) in multivariate analysis. After propensity score matching, median PFS for ARB users was 37.8 months and ARB use remained to be associated with lower recurrence rate in univariate (p=0.035) and multivariate analysis (HR, 0.60; 95% CI, 0.39 to 0.93; p=0.022). Conclusion In this study, ARBs use during primary treatment is associated with lower recurrence in EOC patients. However, CCBs, BBs, and TDs did not show beneficial impact.
Abstract
Purpose We investigated the impact of four types of antihypertensive medications, angiotensin receptor blockers (ARBs), beta blockers (BBs; both selective and non-selective), calcium channel blockers (CCBs), and thiazide diuretics (TDs) on survival outcomes in epithelial ovarian cancer (EOC). Materials and Methods A single-institutional retrospective chart review of 878 patients with EOC was performed. Survival was compared according to use of the four antihypertensive medications during primary treatment. Propensity score matching (ratio 1:3) was performed to control possible associated covariates, such as age, International Federation of Gynecology and Obstetrics stage, residual status after primary debulking surgery, and co-morbidity. Results Among 878 patients, 56 patients (6.4%) were ARB users, 62 (7.1%) were BB users, 107 (12.2%) were CCBs users and 32 (3.6%) used TDs. Median progression-free survival (PFS) for ARB, BB, and CCB users was 37.8, 27.2, and 23.6 months compared with 33.6 months for non-users. ARB was associated with 35% decreased risk of disease progression (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.42 to 0.99; p=0.046) in multivariate analysis. After propensity score matching, median PFS for ARB users was 37.8 months and ARB use remained to be associated with lower recurrence rate in univariate (p=0.035) and multivariate analysis (HR, 0.60; 95% CI, 0.39 to 0.93; p=0.022). Conclusion In this study, ARBs use during primary treatment is associated with lower recurrence in EOC patients. However, CCBs, BBs, and TDs did not show beneficial impact.
참고문헌 (30)
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015", Journal of Gynecologic Oncology, 30(1), pp.1~8 (2019), 대한부인종양학회[DOI]
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- Dolley-Hitze T, "Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?", Br J Cancer, 103, pp.1698~1705 (2010)
- Roder K, "RING finger protein RNF207, a novel regulator of cardiac excitation", J Biol Chem, 289, pp.33730~33740 (2014)
- Leung PS, "A local pancreatic renin-angiotensin system : endocrine and exocrine roles", Int J Biochem Cell Biol, 35, pp.838~846 (2003)
- Liu WB, "Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells", World J Gastroenterol, 11, pp.6489~6494 (2005)
- Gong Q, "Blocking angiotensin II type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells", Pancreas, 39, pp.581~594 (2010)
- Diop-Frimpong B, "Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors", Proc Natl Acad Sci U S A, 108, pp.2909~2914 (2011)
- Zhao Y, "Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma", Proc Natl Acad Sci U S A, 116, pp.2210~2219 (2019)
- Hwang SH, "Expression of angiotensin II receptor type 1 and 2 in ovarian epithelial tumors", Basic Appl Pathol, 1, pp.131~138 (2008)
- Ino K, "Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival", Br J Cancer, 94, pp.552~560 (2006)
- Suganuma T, "Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination", Clin Cancer Res, 11, pp.2686~2694 (2005)
- Park YA, "Dual targeting of angiotensin receptors(AGTR1 and AGTR2)in epithelial ovarian carcinoma", Gynecol Oncol, 135, pp.108~117 (2014)
- Watkins JL, "Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer", Cancer, 121, pp.3444~3451 (2015)
- 백민현, "Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study", Journal of Gynecologic Oncology, 29(6), pp.1~13 (2018), 대한부인종양학회[DOI]
- Heitz F, "Intake of selective beta blockers has no impact on survival in patients with epithelial ovarian cancer", Gynecol Oncol, 144, pp.181~186 (2017)
- Harding BN, "Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer", Gynecol Oncol, 154, pp.426~431 (2019)
- Chehl N, "Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells", J Gastrointest Surg, 13, pp.2189~2200 (2009)
- Wzgarda A, "Unknown face of known drugs - what else can we expect from angiotensin converting enzyme inhibitors?", Eur J Pharmacol, 797, pp.9~19 (2017)
- Matsui T, "Telmisartan inhibits cell proliferation and tumor growth of esophageal squamous cell carcinoma by inducing S-phase arrest in vitro and in vivo", Int J Mol Sci, 20, pp.E3197~ (2019)
- Sood AK, "Stress hormone-mediated invasion of ovarian cancer cells", Clin Cancer Res, 12, pp.369~375 (2006)
- Melhem-Bertrandt A, "Beta-blocker use is associated with improved relapse-free survival in patients with triplenegative breast cancer", J Clin Oncol, 29, pp.2645~2652 (2011)
- Diaz ES, "Impact of beta blockers on epithelial ovarian cancer survival", Gynecol Oncol, 127, pp.375~378 (2012)
- 장해인, "Perioperative administration of propranolol to women undergoing ovarian cancer surgery: A pilot study", Obstetrics & Gynecology Science, 60(2), pp.170~177 (2017), 대한산부인과학회[DOI]
- Eskander R, "Beta blocker use and ovarian cancer survival : a retrospective cohort study", Gynecol Oncol, 127, pp.S21~ (2012)
- Heitz F, "Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG", Gynecol Oncol, 129, pp.463~466 (2013)
- Li W, "Blockade of T-type Ca(2+)channels inhibits human ovarian cancer cell proliferation", Cancer Invest, 29, pp.339~346 (2011)
- Jang SJ, "In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers", Bioorg Med Chem Lett, 23, pp.6656~6662 (2013)
- Sun H, "No association between calcium channel blockers and survival in patients with cancer : a systematic review and meta-analysis", Asian Pac J Cancer Prev, 17, pp.3917~3921 (2016)
- Huang T, "Abstract 4252 : Antihypertensive medication use and ovarian cancer survival", Cancer Res, 78, pp.4252~ (2018)